NAD Press Releases

NAD Recommends Novartis Discontinue Onset-of-Action Claim for Theraflu, following Pfizer Challenge

The NAD has recommended that Novartis Consumer Health Inc., discontinue the advertising claim that “Theraflu Multi-Symptom Severe Cold” “starts to get to work in your body in 5 minutes.” The claim was challenged by Pfizer Consumer Healthcare, a competing manufacturer of cold and cough relief products.

Read More

NAD Refers Advertising Claims from Cortec Corp. to FTC for Further Review

The NAD has referred to the FTC advertising claims made by Cortec Corporation, the maker of vapor corrosion inhibiting (VCI) products, after the advertiser declined to participate in a self-regulatory review of its advertising claims.

Read More

NAD Refers Advertising for Obesity Research Council’s ‘Lipozene’ to FTC for Review after Advertiser Declines to Participate in NAD Proceeding

NAD has referred advertising for Lipozene, a product marketed by the Obesity Research Council, to the Federal Trade Commission (FTC) after the company declined to participate in NAD’s review of its advertising claims.

Read More

NAD Examines Fareportal’s Search Engine Marketing in Challenge Brought by Expedia

NAD has recommended that online travel agent Fareportal Inc. – operator of the CheapOair.com and OneTravel.com sites –discontinue certain claims in its search engine marketing as the claims could potentially mislead consumers when they appear in response to consumer searches.

Read More

Sumo Logic Discontinues Express, Implied Claims Challenged by Splunk

Sumo Logic, Inc., the maker of software for log management and analytic systems, has said it will discontinue all advertising claims challenged before the NAD by competitor Splunk, Inc.

Read More

NAD Recommends ADD-Care Discontinue Claims for Supplement Promoted for ‘Help’ with ADD, ADHD Symptoms

The NAD has recommended that ADD-care, the maker of the dietary supplement ADD-care, discontinue all claims for the product reviewed by NAD in a recent proceeding.

Read More